Sector News

Here’s what’s next for Hospira’s CEO after Pfizer deal

February 9, 2015
Life sciences
Hospira CEO F. Michael Ball is in an admirable position. His turnaround effort at the large injectable-drug maker snagged a coveted offer from pharmaceutical giant Pfizer, which plans to pay nearly 40 percent more per share for Hospira’s stock than it was worth just a day before the deal was announced.
 
So what’s Ball’s fate? Analysts say he’s not likely to stick around.
 
“I would be really shocked to see him stay on at Hospira,” said Michael Waterhouse, an analyst at Chicago-based Morningstar.
 
New York-based Pfizer announced plans yesterday to buy Lake Forest-based Hospira for $17 billion. It’s not clear who Pfizer plans to retain from Hospira, but Ball has earned a reputation for being able to boost the performance of a large, ailing company, said Kevin Kedra, an analyst at Gabelli.
 
Ball pumped more than $487 million into product and quality improvements to address concerns from the U.S. Food and Drug Administration, mainly with troubled manufacturing plants. He inherited a low performer when he took the reins of Hospira in 2011.
 
In the last 12 months, Ball has boosted the stock price from a low of nearly $41 on March 26, 2014, to a high (until Pfizer’s announcement) of about $67 a share on Jan. 26—a 63 percent hike.
 
“Given the job he’s done here, I would think he’d be very much in demand” to become the CEO of another company in need of a turnaround, Kedra said.
 
If Pfizer ends up splitting into two companies, Ball would have a shot at another leadership role, Kedra added.
 
A Hospira spokeswoman did not return messages to comment. Pfizer executives haven’t provided specifics about its future team.
 
“We are very well-aware that Hospira has a lot of talented individuals and have been very successful, as our organization has been successful, so we look to create a combined organization that has the best talent from both organizations,” Pfizer CEO and Chairman Ian Read told analysts during a conference call yesterday.
 
JOB CUTS
 
Meanwhile, the merger could mean job losses at Hospira. Pfizer aims to cut $800 million in costs in the wake of the deal, and analysts say the only way to get there will be through trimming jobs.
 
“I don’t see how they do that without firing (employees),” said Ronny Gal, a senior research analyst at Sanford Bernstein. “Some of it will come from their business presumably, but I don’t see how they would do that without taking out a lot of the cost structure of Hospira.”
 
Hospira has about 19,000 employees worldwide.
 
The deal is expected to close in the second half of the year. Hospira shares closed at $87.64 yesterday.
 
By Kristen Schorsch
 
 

comments closed

Related News

May 21, 2022

As monkeypox cases emerge in US and Europe, Bavarian Nordic inks vaccine order

Life sciences

A monkeypox outbreak is emerging in the U.S. and Europe, and at least one country is amping up countermeasure preparedness. Bavarian Nordic has secured a contract with an unnamed European country to supply its smallpox vaccine, called Imvanex in Europe, in response to the emergence of monkeypox cases, the Danish company said Thursday.

May 21, 2022

Moderna chairman Afeyan defends hiring practices after CFO debacle: report

Life sciences

Moderna’s recent chief financial officer debacle—in which Jorge Gomez departed on his second day on the job—raised questions about the company’s hiring process given its rush to global biopharma prominence. The most obvious one: How was it possible for Gomez to be hired when he was under investigation by his previous employer, Dentsply Sirona of Charlotte, N.C.

May 21, 2022

Merck to pay up to $1.4B in cancer deal with Kelun, but details are scarce

Life sciences

Merck & Co. is plucking a cancer project from the branch of Chinese-based Kelun Pharmaceutical for up to $1.4 billion, but details from the New Jersey-based Big Pharma have been hard to come by. The deal, first disclosed Monday on the Shenzhen stock exchange, has Merck handing over $47 million in upfront cash in exchange for ex-China rights to a “macromolecular tumor project.”